CRISPR/Cas9-mediated mutagenesis to validate the synergy between PARP1 inhibition and chemotherapy in
BRCA1
CRISPR/Cas9
PARP1
precision medicine
synthetic lethality
triple negative breast cancer
Journal
Bioengineering & translational medicine
ISSN: 2380-6761
Titre abrégé: Bioeng Transl Med
Pays: United States
ID NLM: 101689146
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
06
03
2019
revised:
19
11
2019
accepted:
03
12
2019
entrez:
29
1
2020
pubmed:
29
1
2020
medline:
29
1
2020
Statut:
epublish
Résumé
For patients carrying
Identifiants
pubmed: 31989039
doi: 10.1002/btm2.10152
pii: BTM210152
pmc: PMC6971465
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e10152Subventions
Organisme : NIH HHS
ID : S10 OD020056
Pays : United States
Organisme : NCATS NIH HHS
ID : UG3 TR002151
Pays : United States
Informations de copyright
© 2020 The Authors. Bioengineering & Translational Medicine published by Wiley Periodicals, Inc. on behalf of The American Institute of Chemical Engineers.
Références
Sci Adv. 2019 May 22;5(5):eaaw1317
pubmed: 31131324
Biochemistry. 2008 May 27;47(21):5804-13
pubmed: 18452307
Bioanalysis. 2016 May;8(9):921-37
pubmed: 27071838
J Clin Oncol. 2008 Aug 1;26(22):3785-90
pubmed: 18591545
Lancet. 2010 Jul 24;376(9737):235-44
pubmed: 20609467
Lancet Oncol. 2018 Apr;19(4):497-509
pubmed: 29501363
Mol Pharm. 2018 Jul 2;15(7):2742-2753
pubmed: 29750868
Cancer Res. 2013 Apr 1;73(7):2025-30
pubmed: 23536562
Lancet Oncol. 2011 Sep;12(9):852-61
pubmed: 21862407
Genome Biol. 2018 Jun 26;19(1):80
pubmed: 29945655
World J Surg. 2016 Jun;40(6):1362-72
pubmed: 26842691
Prz Menopauzalny. 2016 Dec;15(4):215-219
pubmed: 28250726
Nucleic Acids Res. 2014 Jul;42(Web Server issue):W401-7
pubmed: 24861617
N Engl J Med. 2008 Nov 13;359(20):2143-53
pubmed: 19005198
Genome Biol. 2015 Dec 15;16:280
pubmed: 26671237
J R Soc Interface. 2017 Jun;14(131):
pubmed: 28637915
Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9385-90
pubmed: 19458257
Breast Cancer Res. 2013;15(5):R88
pubmed: 24063698
PLoS One. 2013 May 22;8(5):e64338
pubmed: 23717600
PLoS One. 2015 Oct 15;10(10):e0139846
pubmed: 26468652
Ann Oncol. 2017 Mar 1;28(3):443-447
pubmed: 28057663
J Cell Sci. 2017 Jan 1;130(1):203-218
pubmed: 27663511
Bioinformatics. 2014 May 15;30(10):1473-5
pubmed: 24463181
J Target Ther Cancer. 2018 Feb;7(1):52-69
pubmed: 29577076
N Engl J Med. 2010 Nov 11;363(20):1938-48
pubmed: 21067385
Cancer Res. 2006 Jan 1;66(1):41-5
pubmed: 16397213
Nat Biotechnol. 2019 Mar;37(3):224-226
pubmed: 30809026
Cancer. 2012 Nov 15;118(22):5463-72
pubmed: 22544643
Elife. 2017 Mar 24;6:
pubmed: 28337968
Nat Commun. 2018 May 10;9(1):1849
pubmed: 29748565
Cancer Sci. 2011 Oct;102(10):1882-8
pubmed: 21707865
Nat Protoc. 2013 Nov;8(11):2281-2308
pubmed: 24157548
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Pharmacol Exp Ther. 2014 Jun;349(3):408-16
pubmed: 24650937
Cell. 2018 Apr 19;173(3):665-676.e14
pubmed: 29551272
Adv Sci (Weinh). 2018 May 18;5(7):1700540
pubmed: 30027026
Lab Chip. 2019 Jan 29;19(3):369-386
pubmed: 30644496
Anal Chem. 2014 Mar 18;86(6):2997-3004
pubmed: 24568664